The therapeutic potential of cannabis in multiple sclerosis

Expert Opinion on Investigational Drugs

Volumn 12, Issue 4, 2003, Pages 561-567

  Baker, David ^a   Pryce, Gareth ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cannabinoids; Cannabis; Multiple sclerosis; Neuroprotection; Pain; Spasticity

Indexed keywords

BETA INTERFERON; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS DERIVATIVE; DRONABINOL; GLATIRAMER; MITOXANTRONE; NABILONE; PLACEBO; TETRAHYDROCANNABINOL;

ANALGESIA; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG METABOLISM; DRUG TARGETING; HUMAN; HYDROPHOBICITY; IMMUNE DEFICIENCY; INHIBITION KINETICS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; RELAPSE; REVIEW; SLEEP; SYMPTOM; TREATMENT OUTCOME;

ANIMALS; CANNABINOIDS; CANNABIS; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0037396888     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.4.561     Document Type: Review

References (57)

1. COMPSTON A, COLES A: Multiple sclerosis. Lancet (2002) 359:1221-1231.
2. CONSROE P, MUSTY R, REIN J, TILLERY W, PERTWEE R: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. (1997) 38:44-48.
3. SCHNELLE M, GROTENHERMEN F, REIF M, GORTER RW: Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forsch Komplementärmed (1999) 6(Suppl. 3):28-36.
4. PERTWEE RG: Cannabinoids and multiple sclerosis. Pharmacol. Ther. (2002) 95:165-174.
5. WILLIAMSON EM, EVANS FJ: Cannabinoids in clinical practice. Drugs (2000) 60:1303-1314.
6. MECHOULAM R, HANU L: The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res. Manag. (2001) 6:67-73.
7. KNOLLER N, LEVI L, SHOSHAN I et al.: Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, Phase II clinical trial. Crit. Care Med. (2002) 30:548-554.
8. GROTENHERMEN F: Some practice-relevant aspects of the pharmacokinetics of THC. Forsch Komplementarmed (1999) 6(Suppl. 3):37-39.
9. KILLESTEIN J, HOOGERVORST EL, REIF M et al.: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 58(9):1404-1407.
10. VANEY C, JOBIN P, TSCHOPP F, HEINZEL M, SCHNELLE M: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis. International Cannabinoid Research Society.: 2002 Symposium on the Cannabinoids, Burlington, Vermont, USA (2002):57.
11. FOX P, THOMPSON A, ZAJICEK J: A multicentre randomised controlled trial of cannabinoids in multiple sclerosis. J. Neurol. Sci. (2001) 187:S453.
12. BRADY CM, DAS GUPTA R, WISEMAN OJ, DALTON CM, BERKLEY KJ, FOWLER CJ: The effects of cannabis based medicinal extracts on lower urinary tract dysfunction in advanced multiple sclerosis: preliminary results. J. Neurol. Neurosurg. Psych. (2002) 72:139.
13. NOTCUTT W, PRICE M, SANSOM C, SIMMONS S, PHILLIPS C: Medicinal cannabis extract in chronic pain: Overall results of 29 "N of 1" studies (CBME-1). nternational Cannabinoid Research Society.: 2002 Symposium on the Cannabinoids, Burlington, Vermont, USA (2002):55.
14. ROBSON PJ, WADE DT, MAKELA PM, HOUSE H: Cannabis medicinal extracts (CME), including cannabidiol, alleviated neurogenic systems in patients with multiple sclerosis and spinal cord injury. International Cannabinoid Research Society.: 2002 Symposium on the Cannabinoids, Burlington, Vermont, USA (2002):56.
15. BREIVOGEL CS, CHILDERS SR: The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Dis. (1998) 5:417-431.
16. LUTZ B: Molecular biology of cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:123-142.
17. MCALLISTER SD, GLASS M: CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:161-171.
18. PERTWEE RG: Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem (1999) 6:635-664.
19. REGGIO PH: Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:143-160.
20. SUGIURA T, KOBAYASHI Y, OKA S WAKU K: Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:173-192.
21. DEUTSCH DG, UEDA N, YAMAMOTO S: The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:201-210.
22. CRAVATT BF, DEMAREST K, PATRICELLI MP et al.: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA (2001) 98:9371-9376.
23. LICHTMAN AH, HAWKINS EG, GRIFFIN G, CRAVATT BF: Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther. (2002) 302:73-79.
24. DINH TP, CARPENTER D, LESLIE FM et al.: Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad Sci. USA (2002) 99:10819-10824.
25. WILSON RI, NICOLL RA: Endocannabinoid signaling in the brain. Science (2002) 296:678-682.
26. PERTWEE RG, ROSS RA: Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:101-121.
27. WALKER J, HUANG S: Cannabinoid analgesia. Pharmacol. Ther. (2002) 95:127-135.
28. DEGENHARDTL, HALL W: Cannabis and psychosis. Curr. Psychiatry Rep. (2002) 4:191-196.
29. VAN OS J, BAK M, HANSSEN M, BIJL RV, DE GRAAF R, VERDOUX H: Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. (2002) 156:319-327.
30. MONORY K, TZAVARA ET, LEXIME J et al.: Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem. Biophys. Res. Commun. (2002) 292:231-235.
31. BROOKS JW, PRYCE G, BISOGNO T et al.: Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. J. Pharmacol. (2002) 439:83-92.
32. RICE ASC, FARQUHAR-SMITH WP, NAGY I: Endocannabinoids and pain: spinal and peripheral analgesis in inflammation and neuropathy. Prostaglandins Leukot. Essent. Fatty Acids. (2002) 66:243-256.
33. BAKER D, PRYCE G, CROXFORD JL et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84-87.
34. BAKER D, PRYCE G, CROXFORD JL et al.: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. (2001) 15:300-302.
35. STEINMAN L: Immunotherapy of multiple sclerosis: the end of the beginning. Curr. Opin. Immunol. (2001) 13:597-600.
36. KLEIN TW, NEWTON CA, FRIEDMAN H: Cannabinoids and the immune system. Pain Res. Manag. (2001) 6:95-101.
37. PAROLARO D, MASSI P, RUBINO T, MONTI E: Endocannabinoids in the immune system and cancer. Prostaglandins Leukot. Essent. Fatty Acids. (2002) 66:319-332.
38. MCKALLIP RJ, LOMBARD C, MARTIN BR, NAGARKATTI M, NAGARKATTI PS: Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Ther. (2002) 302:451-465.
39. LYMAN WD, SONETT JR, BROSNAN CF, ELKIN R, BORNSTEIN MB: Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. (1989) 23:73-81.
40. WIRGUIN I, MECHOULAM R, BREUER A, SCHEZEN E, WEIDENFELD J, BRENNER T: Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology (1994) 28:209-214.
41. DI MARZO V, GOPARAJU SK, WANG L et al.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410:822-825.
42. MATARESE G, DI GIACOMO A, SANNA V et al.: Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J. Immunol. (2001) 166:5909-5916.
43. NAHAS GG, SUCIU-FOCA N, ARMAND JP, MORISHIMA A: Inhibition of cellular mediated immunity in marihuana smokers. Science (1974) 183:419-420.
44. BJARTMAR C, TRAPP BD: Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. (2001) 14:271-278.
45. COLES AJ, WING MG, MOLYNEUX P et al.: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. (1999) 46:296-304.
46. WUJEK JR, BJARTMAR C, RICHER E et al.: Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J. Neuropathol. Exp. Neurol. (2002) 61:23-32.
47. GLASS M, DRAGUNOW M, FAULL RL: The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience (2000) 97:505-519.
48. SMITH T, GROOM A, ZHU B, TURSKI L: Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. (2000) 6:62-66.
49. WERNER P, PITT D, RAINE CS: Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. (2001) 50(2):169-180.
50. GUZMAN M, SANCHEZ C, GALVEROPERH I: Cannabinoids and cell fate. Pharmacol. Ther. (2002) 95:175-184.
51. PANIKASHVILI D, SIMEONIDOU C, BEN-SHABAT S et al.: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 413:527-531.
52. GRUNDY RI: The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin. Investig. Drugs. (2002) 11:1365-1374.
53. PRYCE G, HANKEY D, AHMED Z, BAKER D: Cannabinoid treatment and CB1 receptor involvement in inflammatory disease in the CNS. International Cannabinoid Research Society.: 2002 Symposium on the Cannabinoids, Burlington, Vermont, USA (2002):50.
54. DI MARZO V, DE PETROCELLIS L, FEZZA F, LIGRESTI A. BISOGNO, T: Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:377-391.
55. LEVER IJ, MALCANGIO M: CB(1) receptor antagonist SR141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord. Br. J. Pharmacol. (2002) 135:21-24.
56. FOWLER CJ: Intravesical treatment of overactive bladder. Urology (2000) 55(Suppl. 5A):60-64.
57. MACCARRONE M, LORENZON T, BARI M, MELINO G, FINAZZIAGRO A: Anandamide induces apoptosis in human cells via vanilloid receptors.